The EGFR Mutation Test market size was xxx million USD with a CAGR xx % from 2015- 2019. It will stretch to xxx million USD in 2020 with a CAGR of xx % from 2020 to 2025.
Epidermal growth factor receptor (EGFR) is a type of protein, which is located on the surface of human body cells. Any mutation in EGFR gene can lead to various types of cancer. EGFR functions as a biomarker for non-small cell lung cancer (NSCLC) and due to the mutation of EGFR gene a person may suffer from cancer or may have a tumor growth. Tumors with genetically altered EGFR gene are referred to as EGFR-mutated tumors. EGFR mutation is generally observed in NSCLCs, especially in adenocarcinoma tumors. According to the International Association for the Study of Lung Cancer, American Thoracic Society and European Respiratory Society, there are around 50% of surgically resected lung adenocarcinomas in EGFR mutations. These mutations are related to micro papillary predominant subtype and the bronchioloalveolar carcinoma. EGFR biomarker is used in diagnosis of patients with NSCLC. Targeted therapy involving tyrosine kinase inhibitors such as gefitinib and erotinib is used in the treatment of patients with NSCLC. EGFR biomarker detects the presence of specific alterations in EGFR gene, which may lead to the development of tumor.
Increasing global prevalence of lung cancer is expected to fuel growth of As the report focuses on global EGFR Mutation Test market, mainly in Europe and Asia Pacific, North America, Middle East and Africa, and South America. This report segmented the market on the basis of regions, manufacturers, applications, and type.
in addition, this report introduces market competition situation among the vendors and company profile, besides, market price analysis and value chain features are covered in this report.
The key players covered in this study
Abbott
Merck
Thermo Fisher Scientific
Illumina
BioMerieux
QIAGEN
Agilent Technologies
Hologic
Novartis
Roche
Genomic Health
Market Segment by Product Type
DNA Sequencing
Kits
Market Segment by Application
Cancer Hospitals
Clinical Research Institutes
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
Apart from the drivers, restraints, and opportunities, the report also offers competitive landscape, including various growth strategies adopted by profiled players for establishing significant position in the industry. The segmentation included in the comprehensive report will help respectable manufacturers to set up their processing units in the regions and increase their global presence. This would also benefit the industry and increase the company\'s product portfolio.
The research provides answers to the following key questions:
• What is the estimated growth rate and market share and size of the EGFR Mutation Test market for the forecast period 2020 - 2025?
• What are the driving forces in the EGFR Mutation Test market for the forecast period 2020 - 2025?
• Who are the prominent market players and how have they gained a competitive edge over other competitors?
• What are the market trends influencing the progress of the EGFR Mutation Test industry worldwide?
• What are the major challenges and threats restricting the progress of the industry?
• What opportunities does the market hold for the prominent market players?